retatrutide expanded access program How to Get in 2026 Eli Lilly gave mysterious access

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

3 The safety of retatrutide So far, retatrutide looks broadly safe, with side effects that mirror existing GLP-1 medications

Miyamoto, et al., Thermophile-fermented compost as a possible scavenging feed additive to prevent peroxidation

Taken together, these examples suggest that DTP platforms can meaningfully impact patient access and treatment utilization, particularly where affordability and convenience are key drivers